Search
SAR445136
go.drugbank.com/drugs/DB17708InvestigationalHbF production in erythrocytes (RBC). … SAR445136 is an investigational zinc finger nuclease gene-edited cell therapy.
NTx-265
go.drugbank.com/drugs/DB05649InvestigationalIn May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of NTx-265. … NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and differentiation of neural stem cells in adults who have suffered a stroke – the second leading cause
R112
go.drugbank.com/drugs/DB06252ExperimentalR112 is an investigational compound developed to treat Allergic Rhinitis. It's mechanism of action is to inhibit SYK kinase.
NS-3728
go.drugbank.com/drugs/DB05835ExperimentalNS3728 is an orally active chloride channel blocker for the treatment of cancer.
Synonyms: N-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]ureaItolizumab
go.drugbank.com/drugs/DB16207InvestigationalItolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).
Valdecoxib
go.drugbank.com/drugs/DB00580ApprovedWithdrawnValdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.
Vercirnon
go.drugbank.com/drugs/DB15250InvestigationalIt is under investigation in clinical trial NCT01611805 (Japanese Phase I of GSK1605786). … Vercirnon is a novel, orally active anti-inflammatory agent that targets a chemokine receptor protein implicated in both Crohn's disease and ulcerative colitis, the two principal forms of IBD.
International brands: Traficet-ENPMI-001
go.drugbank.com/drugs/DB05730ExperimentalIt is an extract of the roots of an undisclosed perennial shrub which interferes with the production of IL-2 and COX-2 proteins, for the potential treatment of autoimmune diseases, such as rheumatoid arthritis
AGS-16C3F
go.drugbank.com/drugs/DB17551InvestigationalAGS-16C3F is under investigation in clinical trial NCT02639182 (A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma). … AGS 16C3F is an intravenously administered, anti-ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) antibody-drug conjugate.